Greenfield-based Elanco U.S. Inc.’s senior director of companion animal business says an $885 million deal for Boehringer Ingelheim Vetmedica Inc. vaccine products and pipeline shows that parent Eli Lilly and Co. (NYSE: LLY) is committed to the animal health segment. Shawn McKee says the portfolio Elanco acquired "has a loyal following from veterinarians."

During an interview with Inside INdiana Business, McKee said animal health makes up about 20 percent of Lilly’s overall business, and he expects growth.

The acquisition includes dozens of cat, dog and rabies vaccines, as well as a manufacturing facility in Iowa. The deal still has several regulatory hurdles to clear, including approval from the U.S. Federal Trade Commission. McKee expects it to close in the first quarter of 2017.

The portfolio includes vaccines for conditions such as bordetella, Lyme disease, rabies and parvovirus, adding onto Elanco’s current slate of parasiticides, pain medications and dermatology treatments. The facility included in the acquisition is in Fort Dodge Iowa, and includes R&D, testing, on-site vet research and laboratory space.

McKee says the acquisition puts Elanco among the top three animal health companies in the United States.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}